The Future of Targeted Therapy for Leiomyosarcoma

Authors

Ryan A Denu
Amanda M Dann
Emily Z Keung
Michael S Nakazawa
Elise F Nassif Haddad

Publication Date

2-26-2024

Journal

Cancers

Abstract

Leiomyosarcoma (LMS) is an aggressive subtype of soft tissue sarcoma that arises from smooth muscle cells, most commonly in the uterus and retroperitoneum. LMS is a heterogeneous disease with diverse clinical and molecular characteristics that have yet to be fully understood. Molecular profiling has uncovered possible targets amenable to treatment, though this has yet to translate into approved targeted therapies in LMS. This review will explore historic and recent findings from molecular profiling, highlight promising avenues of current investigation, and suggest possible future strategies to move toward the goal of molecularly matched treatment of LMS. We focus on targeting the DNA damage response, the macrophage-rich micro-environment, the PI3K/mTOR pathway, epigenetic regulators, and telomere biology.

Keywords

leiomyosarcoma, genomics, transcriptomics, immunotherapy, precision oncology, targeted therapy

Comments

Supplementary Materials

Data Availability Statement

PMID: 38473300